Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 883-889     DOI: 10.31083/j.rcm2203094
Case Report Previous articles | Next articles
Cardiac amyloidosis presenting with coronary artery embolization
Christos Papageorgiou1, *(), Eleftheria Tsagalou2, Ioannis Baraboutis3, Konstantinos Tampakis4, Efstathios Kastritis2, Meletios-Athanasios Dimopoulos2
1Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
2Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
3Internal Medicine Clinic, Pammakaristos Hospital of Divine Providence, 11144 Athens, Greece
4First Cardiac Department, Henry Dunant Hospital Center, 11526 Athens, Greece
Download:  PDF(317KB)  ( 309 ) Full text   ( 23 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Amyloid light-chain (AL) amyloidosis is a multisystemic disease. Among its clinical manifestations, vein and arterial thromboembolic events are included. We report the unusual case of a 57-year-old female patient with AL amyloidosis presenting with an ST segment elevation myocardial infarction due to coronary artery embolization (CE). The patient reported a history of exertional dyspnoea along with episodes of haemoptysis for the last few months. Her coronary angiography demonstrated embolization of the distal segment of the left anterior descending artery. The main findings of her cardiac ultrasound included concentric left ventricular hypertrophy, mildly impaired left ventricular systolic function, left atrium enlargement and a restrictive-like filling pattern, while her chest computed tomography (CT) demonstrated bilateral pleural effusions. Cardiac magnetic resonance imaging that was performed afterwards, indicated areas of microvascular infarction, a small apex infarct and findings compatible with possible amyloidosis, a diagnosis that was confirmed later by fat tissue biopsy. Patient was referred for an oncology consultation, started therapy with direct oral anticoagulants, angiotensin converting enzyme inhibitor, statins and anti-plasma cell therapy. She has been improving since then and has been free of cardiovascular events for a follow-up period of 12 months. Cardiologists ought to be aware of amyloidosis as a rare but possible cause of coronary embolization, while close collaboration with oncologists is required for the establishment of the correct diagnosis.
Key words:  Cardiomyopathy      Constrictive/restrictive      Coronary blood flow/physiology/microvascular function      Diastolic dysfunction      Cardiac magnetic resonance imaging      Cardio-oncology     
Submitted:  09 March 2021      Revised:  28 June 2021      Accepted:  12 July 2021      Published:  24 September 2021     
*Corresponding Author(s):  Christos Papageorgiou     E-mail:  chrispapageorgio@gmail.com

Cite this article: 

Christos Papageorgiou, Eleftheria Tsagalou, Ioannis Baraboutis, Konstantinos Tampakis, Efstathios Kastritis, Meletios-Athanasios Dimopoulos. Cardiac amyloidosis presenting with coronary artery embolization. Reviews in Cardiovascular Medicine, 2021, 22(3): 883-889.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203094     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/883

[1] Matteo Beltrami, Simone Bartolini, Massimo Milli, Alberto Palazzuoli. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 677-690.
[2] Rafle Fernandez, Francesco Nappi, Sofia A. Horvath, Sarah A. Guigui, Christos G. Mihos. Echocardiographic and clinical outcomes of patients undergoing septal myectomy plus anterior mitral leaflet extension for hypertrophic cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 983-990.
[3] Eyad Abuelgasim, Suleyman Shah, Biyaser Abuelgasim, Nikita Soni, Ashvin Thomas, Mustafa Elgasim, Amer Harky. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 301-314.
[4] Jong-Youn Kim, Eui-Young Choi, Wonho Kim, Se-Joong Rim. Left ventricular outflow obstruction occurs immediately after exercise in patients with non-obstructive hypertrophic cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 469-473.
[5] Nandini Nair. Epidemiology and pathogenesis of heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 531-540.
[6] Nidhi Madan, Dinesh Kalra. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 181-190.
[7] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53-58.
[8] Victoria E. Tril, Alla V. Burlutskaya, Lily V. Polischuk. Metabolic cardiomyopathy in pediatrics[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 73-80.
[9] Juan M. Vinardell, Christos G. Mihos, Adam Nader, Richard Ro, Esteban Escolar, Orlando Santana. Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 65-68.
[10] Saberio Lo Presti, Christos G. Mihos, Evin Yucel, Sofia A. Horvath, Orlando Santana. A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 123-133.
[11] Swapnil Parve, Gulnaz I. Aliakberova, Albert A. Gylmanov, Diana I. Abdulganieva. Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2017, 18(2): 82-87.
[12] George O. Adesina, Shelly A. Hall, Jose C. Mendez, Susan M. Joseph, Robert L. Gottlieb, Parag P. Kale, Amarinder S. Bindra. Arrhythmogenic Right Ventricular Dysplasia: An Under-recognized Form of Inherited Cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 37-43.
[13] Peter A. McCullough, Mohammad Kazem Fallahzadeh, Refaat M. Hegazi. Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 30-39.
[14] Nachiket Patel, Elizabeth Ngo, Timothy E. Paterick, Khawaja Afzal Ammar, Krishnaswamy Chandrasekaran, A. Jamil Tajik. ST-segment Elevation: Myocardial Infarction or Simulacrum?[J]. Reviews in Cardiovascular Medicine, 2016, 17(3-4): 85-99.
[15] Georgios K. Efthimiadis, Efstathios Pagourelias, Thomas Zegkos, Despoina Parcharidou, Theofilos Panagiotidis, Alexandra Arvanitaki, Pavlos Rouskas, Haralambos Karvounis. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives[J]. Reviews in Cardiovascular Medicine, 2016, 17(3-4): 115-123.
No Suggested Reading articles found!